` SKYE (Skye Bioscience Inc) vs S&P 500 Comparison - Alpha Spread

SKYE
vs
S&P 500

Over the past 12 months, SKYE has underperformed S&P 500, delivering a return of -65% compared to the S&P 500's +14% growth.

Stocks Performance
SKYE vs S&P 500

Loading
SKYE
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SKYE vs S&P 500

Loading
SKYE
S&P 500
Difference
www.alphaspread.com

Performance By Year
SKYE vs S&P 500

Loading
SKYE
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Skye Bioscience Inc vs Peers

S&P 500
SKYE
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Skye Bioscience Inc
Glance View

Market Cap
28.8m USD
Industry
Biotechnology

Skye Bioscience, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of cannabinoid-based therapeutics. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2014-02-24. The Company’s products programs include THCVHS and CBDVHS. The firm's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). The company chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.

SKYE Intrinsic Value
1.12 USD
Undervaluation 17%
Intrinsic Value
Price
Back to Top